

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/22-23/BSE-104

Date 14th Feb - 2023

To

Department of Corporate Affairs
BSE Limited
P.J. Towers, Dalal Street
Mumbai -400001

Ref: Script code – 540694

Sub: Outcome of Board Meeting pursuant to Reg. 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Tuesday, 14th February, 2023 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2022 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company.


The Board meeting was commenced at 04:30 P.M. and concluded at 05:45 PM

This is for your information. Kindly take the same on your record.

Thanking you

Yours' faithfully

For ANG Lifesciences India Limited


Rajesh Gupta
(Managing Director)

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter and nine months ended 31 December 2022 (₹ in lakhs except per share data)

Particulars	Quarter ended 31 December 2022	Quarter ended 30 September 2022	Quarter ended 31 December 2021	Nine months ended 31 December 2022	Nine months ended 31 December 2021	Year ended 31 March 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations	4,692.63	5,982.04	4,961.02	18,045.42	25,892.40	35,430.17
II Other income	23.85	16.40	15.58	49.08	33.19	90.13
III Total revenue (I+II)	4,716.48	5,998.44	4,976.60	18,094.50	25,925.59	35,520.30
IV Expenses						
Cost of materials consumed	3,281.33	3,706.20	4,366.00	11,736.94	16,663.64	23,465.10
Changes in inventories of finished goods and work-in-progress	(275.81)	(28.41)	(1,124.24)	-348.88	(580.88)	(666.89)
Employee benefits expense	535.96	656.73	557.90	1,812.44	1,553.03	2,129.01
Finance costs	346.80	331.20	200.24	1,022.47	498.75	890.52
Depreciation and amortisation expenses	212.72	211.03	153.41	632.71	326.91	587.52
Other expenses	875.55	682.98	629.12	2,403.44	2,792.14	3,764.99
Total expenses (IV)	4,976.55	5,559.73	4,782.43	17,259.12	21,253.59	30,170.25
V Profit before exceptional items and tax (III-IV)	(260.07)	438.71	194.17	835.38	4,672.00	5,350.05
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	(260.07)	438.71	194.17	835.38	4,672.00	5,350.05
Tax expense						
(1) Current tax	(62.64)	152.06	65.00	325.73	1,125.00	1,346.50
(2) Deferred tax	(19.87)	23.81	1.84	74.98	40.49	(28.10)
VIII Total tax expense (1+2)	(82.52)	175.87	66.84	400.70	1,165.49	1,318.40
IX Profit for the period (VII-VIII)	(177.55)	262.84	127.33	434.68	3,506.51	4,031.65
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)	0.20	28.87	8.57	115.01	13.75	27.98
Income tax relating to items that will not be reclassified to profit or loss	(0.05)	(7.26)	(2.16)	(28.94)	(3.46)	(7.04)
XI Total comprehensive income (IX+X)	(177.40)	284.45	133.74	520.75	3,516.80	4,052.59
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,295.83	1,036.66	1,305.83	1,036.66	1,036.66
XIII Other equity						7,340.25
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(1.36)	2.20	1.29	3.99	33.92	39.09

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.


Date.....

Statement of standalone unaudited results for the quarter and nine months ended 31 December 2022

(₹ in lakhs except per share data)

Particulars	Quarter ended 31 December 2022	Quarter ended 30 September 2022	Quarter ended 31 December 2021	Nine months ended 31 December 2022	Nine months ended 31 December 2021	Year ended 31 March 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations	4,517.10	5,839.46	4,711.91	17,512.19	25,279.95	34,866.94
II Other income	32.11	20.17	13.46	64.62	32.82	95.15
III Total revenue (I+II)	4,549.21	5,859.63	4,725.37	17,576.81	25,312.77	34,962.09
IV Expenses						
Cost of materials consumed	3,261.65	3,704.72	4,305.66	11,815.06	16,491.89	23,448.55
Changes in inventories of finished goods and work-in-progress	(217.95)	25.07	(1,095.90)	(341.38)	(438.42)	(447.47)
Employee benefits expense	442.80	555.62	477.31	1,547.06	1,330.76	1,832.47
Finance costs	283.58	319.96	168.59	920.99	434.36	785.00
Depreciation and amortisation expenses	191.79	190.12	134.63	570.00	274.99	512.03
Other expenses	816.78	629.84	554.37	2,225.37	2,599.37	3,525.15
Total expenses (IV)	4,778.65	5,425.33	4,544.66	16,737.10	20,692.95	29,655.73
V Profit before exceptional items and tax (III-IV)	(229.44)	434.30	180.71	839.71	4,619.82	5,306.36
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	(229.44)	434.30	180.71	839.71	4,619.82	5,306.36
Tax expense						
(1) Current tax	(62.64)	152.06	65.00	325.73	1,125.00	1,346.50
(2) Deferred tax	(7.23)	20.16	(6.17)	77.17	51.71	(11.44)
VIII Total tax expense (1+2)	(69.87)	172.22	58.83	402.90	1,176.71	1,335.06
IX Profit for the period (VII-VIII)	(159.57)	262.08	121.88	436.81	3,443.11	3,971.30
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)	(0.24)	28.17	8.57	113.53	13.75	27.98
Income tax relating to items that will not be reclassified to profit or loss	0.06	(7.09)	(2.16)	(28.57)	(3.46)	(7.04)
XI Total comprehensive income (IX+X)	(159.75)	283.16	128.29	521.77	3,453.40	3,992.24
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,295.83	1,036.66	1,305.83	1,036.66	1,036.66
XIII Other equity						7,311.45
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(1.22)	2.19	1.24	4.00	33.31	38.51

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December	30 September	31 December	31 December	31 December	31 March
		2022	2022	2021	2022	2021	2022
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue						
	a) Pharmaceuticals	4,517.10	5,839.46	4,711.91	17,512.19	25,279.95	34,866.94
	b) Printing and packagings	337.69	372.94	507.66	1,696.07	1,476.59	2,189.68
	Total	4,854.79	6,212.40	5,219.57	19,208.26	26,756.54	37,056.62
	Less: Inter segment revenue	162.16	230.37	258.54	1,162.84	864.14	1,626.45
	Revenue from operations	4,692.63	5,982.03	4,961.03	18,045.42	25,892.40	35,430.17
2	Segment results (profit before tax and finance cost from each segment)						
	a) Pharmaceuticals	46.48	747.91	345.37	1,744.71	5,044.18	6,084.22
	b) Printing and packagings	40.25	22.00	49.04	113.14	126.57	156.35
	Total	86.73	769.91	394.41	1,857.85	5,170.75	6,240.57
	Less: Finance costs	346.80	331.20	200.24	1,022.47	498.75	890.52
	Profit before tax	(260.07)	438.71	194.17	835.38	4,672.00	5,350.05
	Particulars			As at	As at	As at	As at
				31 December	30 September	31 December	31 March
				2022	2022	2021	2022
3	Segment Assets						
	a) Pharmaceuticals			25,763.82	26,675.96	24,653.81	26,511.12
	b) Printing and packagings			2,496.30	2,287.34	2,336.67	2,591.92
	Total Segment assets			28,260.12	28,963.30	26,990.48	29,103.04
4	Segment liabilities						
	a) Pharmaceuticals			16,698.89	17,458.30	16,411.09	18,200.11
	b) Printing and packagings			2,463.57	2,429.94	2,616.06	2,526.01
	Total Segment liabilities			19,162.46	19,888.24	19,027.14	20,726.12



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2022 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 February 2023. The Statutory Auditors have conducted "Limited Review" of these results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have expressed unmodified report on the above results.
3. The above unaudited standalone and consolidated financial results of the Company and the Group have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, Companies (Indian Accounting Standard) Amendment Rules, 2016 and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) and other accounting principles generally accepted in India.
4. During the period ended 31 December 2022, the Company has issued 2,591,657 bonus shares on the record date i.e. 14 July 2022 in the proportion of 1 (One) equity share of Rs.10 each for every 4 (Four) Equity Shares of Rs.10 each held by the shareholders of the Company as on the record date.
5. During the quarter and period ended 31 December 2022, the Company has allotted 100,000 equity shares at the price of Rs.200 per equity share(face value of Rs.10 plus premium of Rs. 190) on preferential basis on 29 November 2022.
6. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
7. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

Rajesh Gupta ★
(Managing Director)

Place: Amritsar

Date: 14 February 2023



Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

Independent Auditor's Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of ANG Lifesciences India Limited ("Holding Company") and its Subsidiary (the Holding and its subsidiaries together referred to as "the Group") for the quarter ended 31st December, 2022 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-
Mansa Print & Publishers Limited





Raman Wadhwa & Co.



CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Amritsar
Date: 14.02.2023

For Raman Wadhwa & Co.
Chartered Accountants

(Ishant Sharma)
Partner

Reg. no. 012037N

M. No. 527055

UDIN: 23527055 BGR00 B22 05



Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

Independent Auditor's Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 31st December, 2022 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principle laid down in the applicable Indian Accounting Standards (Ind-As) specified under section 133 of the companies Act, 2013, read with applicable rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Amritsar
Date: 14.02.2023

For Raman Wadhwa & Co.
Chartered Accounts

(Ishant Sharma)
Partner
Reg. no. 012037N
M. No. 527055

UDIN: 23527055BC1R0QD7450